Bespak
Holmes Chapel (HQ), UK
Finished Product Manufacturing
+44 (0) 1477 537 112
Bespak Holmes Chapel
London Road
Holmes Chapel
Crewe
Cheshire
CW4 8BE
UK
W: https://bespak.com/

King’s Lynn UK
Components & Devices
+44 (0) 1553 691 000
Bespak King’s Lynn
Bergen Way
North Lynn Industrial Estate
King’s Lynn
Norfolk
PE30 2JJ
UK

Bespak – the specialist inhalation CDMO committed to leading the transition to low carbon pMDIs.

Bespak® is a global Contract Development and Manufacturing Organisation (CDMO) solely focused on inhaled and nasal drug delivery. Headquartered in Holmes Chapel, UK, the company develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical industry. Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation development, product development and clinical supply, through to full-scale cGMP batch production.

With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak is the first CDMO with commercial capacity for manufacturing low carbon pMDIs using both low Global Warming Potential (GWP) propellants, HFA-152a and HFO-1234ze. Bespak supplies a major proportion of the world’s pMDI metering valves and actuators, including the trusted, market approved BK357 valve, which has now been optimised for reliable compatibility with next-generation propellants and is the first and only valve approved for this use. Leveraging established capabilities, ongoing manufacturing expansions, and collaborations across the supply chain, Bespak is leading the transition to low carbon pMDIs.

Bespak also specialises in the industrialisation and high-volume manufacture of complex Dry Powder Inhaler (DPI) devices, as well as unit dose and multi dose nasal sprays, offering industry-leading contract manufacturing services at all scales.

Across drug-device combination product development and manufacturing, Bespak delivers industry-leading quality supported by continuous improvement. Investing in the long-term capabilities of its workforce, , the company’s unique Injection Moulding Academy enables technological innovation through expert-led training in inhalation device manufacture. Bespak also recognises the complexity of regulatory pathways for drug-device combination products and provides specialist support to help de-risk and streamline development.

Through a joint venture with Medspray, Bespak offers Resyca® Soft Mist Inhalers (SMIs) and nasal soft mist atomisers. These harness proprietary spray nozzle technology to efficiently deliver sensitive formulations, including biologics, to the lungs or nasal cavity.

Bespak’s expanding capabilities are strengthened by significant investment and strategic collaborations. Working alongside its partners, Bespak is helping to lead the inhalation industry to a more sustainable future and supporting continued patient access to life-saving treatments.

Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. This commitment extends across its operations, as Bespak prioritises strong environmental, social and governance (ESG) strategies to build responsible business practices and establish itself as a trusted partner for its customers.